首页> Blood advances> A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Joseph M,Tuscano

第一单位： Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA.;Section of Hematology and Oncology, Veterans Administration Northern California Healthcare System, Mather, CA.

作者： Joseph M,Tuscano ^[1] ; Tamer,Othman ^[2] ; Paul,Frankel ^[3] ; Christopher,Ruel ^[3] ; Christina,Poh ^[3] ; Samantha,Herbert ^[4] ; Emanual,Maverakis ^[4] ; Alexander A,Merleev ^[4] ; Guillaume,Luxardi ^[4] ; Mehrdad,Abedi ^[4] ; Raghuveer,Ranganathan ^[5] ; Dipenkumar,Modi ^[6] ; Jasmine,Zain ^[3] ; Elizabeth L,Budde ^[3] ; Matthew,Mei ^[3] ; Aaron S,Rosenberg ^[4] ; Rasmus T,Hoeg ^[4] ; Caitlin,Costello ^[7] ; Francine M,Foss ^[8] ; Basem M,William ^[9] ; H Kent,Holland ^[10] ; Elad,Sharon ^[11] ; Howard,Streicher ^[12] ; Alexey V,Danilov ^[3] ; Edward,Newman ^[12]

作者单位： Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA.;Section of Hematology and Oncology, Veterans Administration Northern California Healthcare System, Mather, CA. ^[1] Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA. ^[2] Department of Biostatistics, City of Hope, Duarte, CA. ^[3] Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA. ^[4] Division of Hematology and Oncology University of Southern California, Los Angeles, CA. ^[5] Division of Hematology and Oncology, Karmanos Cancer Institute, Detroit, MI. ^[6] Division of Hematology and Oncology, University of California San Diego, La Jolla, CA. ^[7] Section of Medical Oncology, Yale Cancer Center, New Haven, CT. ^[8] Department of Hematology and Oncology, The Ohio State University, Columbus, OH. ^[9] Department of Blood and Marrow Transplantation at Northside Hospital, Atlanta, GA. ^[10] Department of Medicine, Dana-Farber Cancer Institute, Boston, MA. ^[11] Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. ^[12]

医学主题词人类(Humans);抗体, 双特异性(Antibodies, Bispecific);中年人(Middle Aged);女(雌)性(Female);男(雄)性(Male);老年人(Aged);淋巴瘤, B细胞(Lymphoma, B-Cell);成年人(Adult);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);最大耐受剂量(Maximum Tolerated Dose);治疗结果(Treatment Outcome);复发(Recurrence);老年人, 80以上(Aged, 80 and over)

DOI 10.1182/bloodadvances.2025016845

PMID 41213001

发布时间 2026-05-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2026年10卷4期

1153-1162页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Blood advances

2026年10卷4期

1153-1162页

检索历史清除

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

检索历史清除